HIF1A and breast carcinoma: Furthermore, HIF-1 suppression and DC-based immunotherapy were confirmed to enhance survival in a breast cancer model by enhancing the proliferation and activities of cytotoxic T cells and enhancing the synthesis of type 1 interferon (IFN) [70].